We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:

  • A company with a novel proprietary first-in-class immunotherapy platform for solid and liquid tumors, with four clinical candidates, the most advanced in Ph II trials, available for licensing.
  • A company with a novel, proprietary, first-in-class humanized monoclonal antibody for the treatment of wet AMD, diabetic retinopathy and diabetic macular edema available for licensing.
  • A company with several targeted clinical-stage products based on their ceremide technology for orphan oncology indications, including PTCL, CTCL and neuroblastoma that are available for licensing.
  • A company with a novel treatment for short bowel syndrome, an orphan GI disorder with composition of matter, available for EU licensing.
Download our presentation
PDF

Get a digital copy of our PDF presentation

Download PDF